Skip to main content

About Cancer Research KI

Cancer Research KI serves as an overarching umbrella organisation for cancer research at Karolinska Institutet, conducted by some 250 research groups at multiple campuses and departments. The overall goal is to generate new scientific discoveries that can be rapidly translated into clinical practice for the benefit of patients and society.

Organisation

Cancer Research KI was formed 2019 as the Strategic Research Programme in Cancer (StratCan) and the KICancer network joined forces. The programme is supported by the government through the strategic initiatives.

Cancer Research KI Steering Board:

Jonas Bergh

Director Cancer Research KI
Department of Oncology-Pathology (OnkPat), K7

Kamila Czene

Co-Director Cancer Research KI
Department of Medical Epidemiology and Biostatistics (MEB), C8

Urban Lendahl

Co-Director Cancer Research KI
Department of Cell and Molecular Biology (CMB), C5

Martin Bergö

Professor
Department of Biosciences and Nutrition (BioNut), H2

Lisa Westerberg

Senior researcher
Department of Microbiology, Tumor and Cell Biology (MTC), C1

Yvonne Wengström

Professor/nurse
Department of Neurobiology, Care Sciences and Society (NVS), H1

Ingemar Ernberg

Professor, senior
Department of Microbiology, Tumor and Cell Biology (MTC), C1
Department of Medicine, Huddinge (MedH), H7

Bertrand Joseph

Professor
Institute of Environmental Medicine (IMM), C6

Klas Blomgren

Professor/senior physician
Department of Women's and Children's Health (KBH), K6

Eva Hellström Lindberg

Professor/senior physician
Department of Medicine, Huddinge (MedH), H7

Randall Johnson

Professor
Department of Cell and Molecular Biology (CMB), C5
Department of Oncology-Pathology (OnkPat), K7

Maria Kasper

Senior researcher
Department of Biosciences and Nutrition (BioNut), H2

Sonia Lain

Professor
Department of Microbiology, Tumor and Cell Biology (MTC), C1

Andreas Lundqvist

Gruppchef
Department of Oncology-Pathology (OnkPat), K7

Background

In 2009 the Swedish Government designated in the Government Bill on Research Policy that 20 strategic research areas were to be prioritized; Cancer was one area. Cancer is represented nationally by three programmes: Cancer Research KI (formerly StratCan) at Karolinska Institutet, U-CAN (Universities of Uppsala & Umeå) and BioCare (Universities of Lund & Gothenburg).

Cancer as a strategic research area is motivated by the fact that cancer is one of the world's most common diseases and a major cause of death. In Sweden it is expected that cancer incidence will continue to rise and that cancer prevalence will double by 2030. New research strategies aiming at effective prevention and improved treatment are therefore urgently needed.